Efter aflæggelse af Q2 regnskabet afholdte Novo Nordisk ledelse med analytikerne, deres investorpræsentation som kan ses via dette link. Her har man mulighed for at høre Q&A med analytikerne efter ledelsens indledende præsentation.
Novo Nordisk indleder præsentationen sådan:
| In DKK million | First six months of 2020 |
| Sales | 63,881 |
| Gross profit | 53,723 |
| Gross margin | 84.1% |
| Sales and distribution costs | 14,988 |
| Percentage of sales | 23.5% |
| Research and development costs | 7,068 |
| Percentage of sales | 11.1% |
| Administration costs | 1,754 |
| Percentage of sales | 2.7% |
| Other operating income, net | 227 |
| Operating profit | 30,14 |
| Operating margin | 47.2% |
| Financial items (net) | -1,703 |
| Profit before income tax | 28,437 |
| Income taxes | 5,915 |
| Effective tax rate | 20.8% |
| Net profit | 22,522 |
| Diluted earnings per share (DKK) | 9.58 |
